Albany, NY -- (SBWIRE) -- 11/05/2015 -- Originally developed by Takeda Pharmaceutical Co., Ltd, leuprorelin is a polypeptide used to treat prostate cancer and so on. Leuprorelin can inhibit pituitary gland and release gonadotropin Leuprolide acts as an agonist at pituitary GnRH receptors, leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes.

Having been marketed in 1994 for the first time, leuprorelin entered China under the trade name of enantone in 2000. As it is the specific drug for such sex hormone-related diseases as prostate cancer and endometriosis, it grows fast in China. Due to the technology involved in production of polypeptide, there was no generic drug for a long time despite its lack of patent protection in China. Currently, only generic drugs of Beijing Biote and Livzon are approved.

Download Free Sample report with report structure at: http://www.researchmoz.us/enquiry.php?type=S&repid=449878

Leuprorelin develops fast after entering China with sales value in sample hospitals rising from about CNY 20 million in 2005 to over CNY 260 million in 2014 and CAGR during the period of 2006-2010 reaching 37%. Leuprorelin enjoys a vast demand in China. And Livzon, Beijing Biote Pharmaceutical Co., Ltd and Takeda Pharmaceutical Co., Ltd (Japan) occupy the market, among which Takeda Pharmaceutical Co., Ltd (Japan) had the largest market share of nearly 60% for sales value in 2014.

Due to unreliable heat of diet, Chinese children report increasingly obvious symptoms of sexual precocity, which is bad for their healthy development and attracts more and more parents' attention. In recent years, such problems as female fibroid caused by abnormal secretion of hypophyseal hormone have become increasingly prominent. As these problems are increasingly emphasized, leuprorelin which regulates the secretion of gonadotropins will enjoy a vast market. Since Lee's Pharmaceutical Holdings Limited is now the only company which applied to produce generic drugs of leuprorelin, there are still opportunities for future generic drugs.

Browse complete Report description with TOC at: http://www.researchmoz.us/investigation-report-on-china-leuprorelin-market-20102019-report.html

Readers can get at least the following information through this report:

market size of leuprorelin in China
competitive landscape of leuprorelin market in China
price of leuprorelin made by different enterprises in China
market outlook of leuprorelin in China
The author suggests the following groups of people purchase this report:
manufacturers of polypeptide drugs
investors/research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service

Submit your (Query / Enquiry) at: http://www.researchmoz.us/enquiry.php?type=E&repid=449878

About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us